Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

MMM

Key Information for 3M Investors

We've been asking ourselves recently if the market has placed a fair valuation on 3M. Let's dive into some of the fundamental values of this Large-Cap Health Care company to determine if there might be an opportunity here for value-minded investors.

a Very Low P/E Ratio but Priced at a Premium:

3M Company provides diversified technology services in the Americas, the Asia Pacific, Europe, the Middle East, Africa, and internationally. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) ratio of 3.19. In contrast, 3M has a trailing 12 month P/E ratio of 20.4 and a P/B ratio of 18.23.

3M has moved 15.9% over the last year compared to 16.8% for the S&P 500 — a difference of -0.9%. 3M has a 52 week high of $164.15 and a 52 week low of $119.31.

The Company's Revenues Are Declining:

2019 2020 2021 2022 2023 2024
Revenue (M) $32,136 $32,184 $35,355 $26,161 $24,610 $24,575
Operating Margins 19% 22% 21% 17% -43% 20%
Net Margins 14% 17% 17% 22% -28% 17%
Net Income (M) $4,517 $5,449 $5,921 $5,777 -$6,995 $4,173
Net Interest Expense (M) $448 $529 $488 $462 $942 $472
Depreciation & Amort. (M) $1,593 $1,911 $1,915 $1,831 $1,987 $1,363
Diluted Shares (M) 585 582 585 568 554 552
Earnings Per Share $7.72 $9.36 $10.12 $10.18 -$12.63 $7.55
EPS Growth n/a 21.24% 8.12% 0.59% -224.07% 159.78%
Avg. Price $153.7 $141.75 $172.25 $142.06 $98.98 $146.62
P/E Ratio 19.63 15.03 16.84 13.91 -7.84 19.34
Free Cash Flow (M) $5,371 $6,612 $5,851 $3,842 $5,065 $638
CAPEX (M) $1,699 $1,501 $1,603 $1,749 $1,615 $1,181
EV / EBITDA 13.25 10.64 12.26 15.38 -7.58 14.62
Total Debt (M) $22,154 $19,589 $18,654 $17,877 $17,187 $14,963
Net Debt / EBITDA 1.86 1.65 1.52 2.29 -1.32 1.51
Current Ratio 1.41 1.89 1.7 1.54 1.07 1.41
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS